| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 62 | 2022 | 807 | 5.560 |
Why?
|
| Heart Failure | 67 | 2023 | 1253 | 4.980 |
Why?
|
| Ventricular Function, Left | 22 | 2023 | 613 | 2.060 |
Why?
|
| Hemodynamics | 24 | 2022 | 738 | 2.000 |
Why?
|
| Heart Ventricles | 19 | 2021 | 786 | 1.910 |
Why?
|
| MicroRNAs | 7 | 2017 | 556 | 1.770 |
Why?
|
| Heart Transplantation | 12 | 2021 | 731 | 1.350 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2017 | 200 | 1.340 |
Why?
|
| Pulmonary Wedge Pressure | 12 | 2021 | 113 | 1.190 |
Why?
|
| Middle Aged | 92 | 2023 | 26146 | 1.090 |
Why?
|
| Myocardium | 6 | 2017 | 573 | 0.990 |
Why?
|
| Aortic Valve Insufficiency | 7 | 2020 | 132 | 0.990 |
Why?
|
| Cardiac Catheterization | 12 | 2020 | 307 | 0.990 |
Why?
|
| Humans | 146 | 2023 | 89961 | 0.960 |
Why?
|
| Male | 107 | 2023 | 42674 | 0.950 |
Why?
|
| Female | 102 | 2023 | 46587 | 0.930 |
Why?
|
| Prosthesis Implantation | 7 | 2020 | 129 | 0.920 |
Why?
|
| Cardiomyopathies | 6 | 2020 | 267 | 0.910 |
Why?
|
| Cornea | 2 | 2014 | 70 | 0.870 |
Why?
|
| Skin Neoplasms | 6 | 2020 | 598 | 0.860 |
Why?
|
| Ventricular Remodeling | 3 | 2021 | 108 | 0.820 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 521 | 0.790 |
Why?
|
| Myocytes, Cardiac | 6 | 2016 | 314 | 0.770 |
Why?
|
| Echocardiography | 16 | 2020 | 944 | 0.760 |
Why?
|
| Skin | 6 | 2020 | 589 | 0.760 |
Why?
|
| S100 Proteins | 5 | 2013 | 52 | 0.740 |
Why?
|
| Gene Expression Regulation | 9 | 2017 | 1983 | 0.740 |
Why?
|
| Folliculitis | 1 | 2020 | 2 | 0.700 |
Why?
|
| Mesotherapy | 1 | 2020 | 2 | 0.700 |
Why?
|
| Echocardiography, Doppler | 8 | 2020 | 187 | 0.690 |
Why?
|
| Foot Diseases | 1 | 2019 | 12 | 0.690 |
Why?
|
| Foot | 1 | 2019 | 52 | 0.670 |
Why?
|
| Aged | 57 | 2023 | 19254 | 0.670 |
Why?
|
| Hemangioma | 1 | 2019 | 64 | 0.660 |
Why?
|
| Signal Transduction | 9 | 2020 | 3404 | 0.660 |
Why?
|
| Gap Junctions | 2 | 2017 | 144 | 0.650 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 469 | 0.620 |
Why?
|
| Treatment Outcome | 35 | 2023 | 8273 | 0.610 |
Why?
|
| Melanoma | 4 | 2020 | 471 | 0.610 |
Why?
|
| Cannula | 6 | 2020 | 50 | 0.600 |
Why?
|
| Cosmetic Techniques | 2 | 2015 | 29 | 0.600 |
Why?
|
| Cardiology | 1 | 2019 | 115 | 0.590 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 2393 | 0.580 |
Why?
|
| Biopsy | 5 | 2019 | 1184 | 0.580 |
Why?
|
| Desmosomes | 1 | 2017 | 10 | 0.570 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 10 | 0.570 |
Why?
|
| Retrospective Studies | 34 | 2022 | 9210 | 0.560 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 716 | 0.560 |
Why?
|
| Adult | 45 | 2023 | 26816 | 0.540 |
Why?
|
| Prospective Studies | 26 | 2023 | 4329 | 0.540 |
Why?
|
| Heart Atria | 2 | 2019 | 282 | 0.540 |
Why?
|
| Intra-Aortic Balloon Pumping | 4 | 2020 | 80 | 0.540 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 7 | 0.540 |
Why?
|
| Cryptococcosis | 1 | 2016 | 11 | 0.540 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 142 | 0.540 |
Why?
|
| Cellulitis | 1 | 2016 | 19 | 0.540 |
Why?
|
| Fungemia | 1 | 2016 | 15 | 0.540 |
Why?
|
| Regeneration | 1 | 2017 | 151 | 0.540 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2016 | 35 | 0.530 |
Why?
|
| Methanobrevibacter | 2 | 2013 | 2 | 0.520 |
Why?
|
| Hemorrhage | 4 | 2018 | 287 | 0.510 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 979 | 0.510 |
Why?
|
| Acupuncture Therapy | 1 | 2015 | 10 | 0.500 |
Why?
|
| Heart Conduction System | 2 | 2012 | 112 | 0.500 |
Why?
|
| Cell Nucleus | 2 | 2017 | 602 | 0.490 |
Why?
|
| Sclerosis | 1 | 2015 | 29 | 0.490 |
Why?
|
| Medical Oncology | 1 | 2019 | 384 | 0.490 |
Why?
|
| Leg Ulcer | 1 | 2014 | 7 | 0.490 |
Why?
|
| Granuloma | 1 | 2015 | 65 | 0.480 |
Why?
|
| Animals | 38 | 2020 | 27528 | 0.480 |
Why?
|
| Tetracaine | 1 | 2014 | 1 | 0.480 |
Why?
|
| Thrombosis | 5 | 2020 | 302 | 0.480 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 30 | 0.480 |
Why?
|
| Eye Pain | 1 | 2014 | 4 | 0.480 |
Why?
|
| Corneal Injuries | 1 | 2014 | 10 | 0.480 |
Why?
|
| Embolism | 1 | 2014 | 33 | 0.480 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2012 | 46 | 0.470 |
Why?
|
| Eye Injuries | 1 | 2014 | 14 | 0.470 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 432 | 0.470 |
Why?
|
| Cardiac Output | 6 | 2022 | 155 | 0.470 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2014 | 2 | 0.460 |
Why?
|
| Lasers, Excimer | 1 | 2014 | 5 | 0.460 |
Why?
|
| Face | 1 | 2015 | 118 | 0.460 |
Why?
|
| Photorefractive Keratectomy | 1 | 2014 | 4 | 0.460 |
Why?
|
| Myopia | 1 | 2014 | 10 | 0.460 |
Why?
|
| Foreign Bodies | 1 | 2014 | 66 | 0.450 |
Why?
|
| Prednisone | 3 | 2020 | 255 | 0.450 |
Why?
|
| Anesthetics, Local | 1 | 2014 | 77 | 0.450 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2020 | 145 | 0.450 |
Why?
|
| Cardiomegaly | 6 | 2016 | 120 | 0.450 |
Why?
|
| Trigeminal Nerve | 1 | 2013 | 18 | 0.450 |
Why?
|
| Connexin 43 | 1 | 2014 | 94 | 0.440 |
Why?
|
| Thromboembolism | 3 | 2018 | 122 | 0.440 |
Why?
|
| Nerve Fibers | 1 | 2013 | 48 | 0.430 |
Why?
|
| Device Removal | 3 | 2020 | 168 | 0.430 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 3678 | 0.430 |
Why?
|
| Panniculitis | 1 | 2013 | 10 | 0.430 |
Why?
|
| Fox-Fordyce Disease | 1 | 2012 | 2 | 0.420 |
Why?
|
| Lactoglobulins | 1 | 2012 | 8 | 0.420 |
Why?
|
| Xanthomatosis | 1 | 2012 | 5 | 0.420 |
Why?
|
| Hypertrichosis | 1 | 2012 | 4 | 0.420 |
Why?
|
| Neurocytoma | 1 | 2012 | 3 | 0.420 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 25 | 0.410 |
Why?
|
| Heart | 4 | 2019 | 578 | 0.410 |
Why?
|
| Methane | 1 | 2012 | 13 | 0.400 |
Why?
|
| Mice | 24 | 2020 | 11851 | 0.400 |
Why?
|
| Mice, Transgenic | 13 | 2019 | 1576 | 0.390 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2013 | 152 | 0.390 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 388 | 0.390 |
Why?
|
| Constipation | 1 | 2012 | 64 | 0.380 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2011 | 4 | 0.380 |
Why?
|
| Facial Dermatoses | 1 | 2011 | 13 | 0.380 |
Why?
|
| Indoles | 1 | 2013 | 300 | 0.380 |
Why?
|
| Postoperative Complications | 9 | 2020 | 2314 | 0.370 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 1606 | 0.360 |
Why?
|
| Sulfonamides | 1 | 2013 | 319 | 0.360 |
Why?
|
| Sirtuin 3 | 4 | 2016 | 30 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 4 | 2020 | 366 | 0.360 |
Why?
|
| Arterial Pressure | 3 | 2020 | 38 | 0.350 |
Why?
|
| Lymphedema | 3 | 2020 | 77 | 0.340 |
Why?
|
| Histiocytosis, Sinus | 2 | 2020 | 15 | 0.340 |
Why?
|
| Liver Transplantation | 4 | 2021 | 1175 | 0.340 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2021 | 518 | 0.330 |
Why?
|
| Recovery of Function | 4 | 2019 | 298 | 0.330 |
Why?
|
| CD18 Antigens | 1 | 2009 | 22 | 0.330 |
Why?
|
| Methotrexate | 2 | 2020 | 243 | 0.330 |
Why?
|
| Kidney Transplantation | 3 | 2021 | 856 | 0.320 |
Why?
|
| Aortic Valve | 4 | 2020 | 246 | 0.320 |
Why?
|
| Atrial Fibrillation | 4 | 2019 | 357 | 0.320 |
Why?
|
| Tricuspid Valve | 2 | 2020 | 99 | 0.320 |
Why?
|
| Heart Defects, Congenital | 3 | 2021 | 365 | 0.320 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 89 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 798 | 0.310 |
Why?
|
| Autoimmune Diseases | 3 | 2021 | 250 | 0.310 |
Why?
|
| Pulmonary Artery | 3 | 2021 | 323 | 0.310 |
Why?
|
| Counterpulsation | 2 | 2018 | 21 | 0.310 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 116 | 0.300 |
Why?
|
| Cardiotonic Agents | 3 | 2019 | 90 | 0.300 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 96 | 0.300 |
Why?
|
| Lymph Node Excision | 2 | 2019 | 220 | 0.300 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2020 | 179 | 0.290 |
Why?
|
| Coronary Artery Bypass | 3 | 2020 | 236 | 0.290 |
Why?
|
| Radiotherapy | 2 | 2019 | 332 | 0.290 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2020 | 239 | 0.290 |
Why?
|
| Photosensitivity Disorders | 1 | 2007 | 15 | 0.280 |
Why?
|
| Lichen Planus | 1 | 2007 | 10 | 0.280 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 389 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2023 | 332 | 0.280 |
Why?
|
| Graft Rejection | 4 | 2021 | 1076 | 0.280 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 191 | 0.280 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2013 | 241 | 0.270 |
Why?
|
| Energy Metabolism | 2 | 2019 | 282 | 0.270 |
Why?
|
| Wound Healing | 2 | 2020 | 361 | 0.270 |
Why?
|
| Psoriasis | 1 | 2009 | 245 | 0.260 |
Why?
|
| Leiomyomatosis | 1 | 2005 | 12 | 0.260 |
Why?
|
| Time Factors | 12 | 2021 | 5358 | 0.260 |
Why?
|
| Ventricular Function, Right | 4 | 2020 | 150 | 0.250 |
Why?
|
| Transcription Factors | 2 | 2014 | 1664 | 0.250 |
Why?
|
| Oxidative Stress | 4 | 2019 | 458 | 0.240 |
Why?
|
| Nails, Malformed | 1 | 2004 | 3 | 0.240 |
Why?
|
| Mitochondria | 3 | 2019 | 556 | 0.240 |
Why?
|
| Urticaria | 1 | 2004 | 14 | 0.240 |
Why?
|
| Craniofacial Abnormalities | 1 | 2004 | 36 | 0.240 |
Why?
|
| Hair | 1 | 2004 | 56 | 0.240 |
Why?
|
| Stroke Volume | 4 | 2023 | 479 | 0.240 |
Why?
|
| Cold Temperature | 1 | 2004 | 160 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 39 | 0.230 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1243 | 0.230 |
Why?
|
| Aminobutyrates | 2 | 2023 | 13 | 0.220 |
Why?
|
| Tetrazoles | 2 | 2023 | 24 | 0.220 |
Why?
|
| Osteopoikilosis | 1 | 2003 | 1 | 0.220 |
Why?
|
| Skin Diseases, Genetic | 1 | 2003 | 3 | 0.220 |
Why?
|
| Patient Readmission | 4 | 2020 | 355 | 0.220 |
Why?
|
| Sirtuins | 3 | 2016 | 46 | 0.220 |
Why?
|
| Abnormalities, Multiple | 1 | 2004 | 234 | 0.210 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 26 | 0.210 |
Why?
|
| Anticoagulants | 4 | 2019 | 432 | 0.210 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 1221 | 0.210 |
Why?
|
| Survival Rate | 7 | 2021 | 1899 | 0.200 |
Why?
|
| Transplant Recipients | 2 | 2021 | 142 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 848 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 414 | 0.200 |
Why?
|
| Complement C3d | 1 | 2021 | 6 | 0.200 |
Why?
|
| NIH 3T3 Cells | 2 | 2014 | 110 | 0.190 |
Why?
|
| Aortic Aneurysm | 2 | 2014 | 80 | 0.190 |
Why?
|
| 3' Untranslated Regions | 2 | 2014 | 95 | 0.190 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2021 | 18 | 0.190 |
Why?
|
| Blood Flow Velocity | 2 | 2019 | 200 | 0.190 |
Why?
|
| Complement C4b | 1 | 2021 | 32 | 0.190 |
Why?
|
| Bone and Bones | 1 | 2003 | 271 | 0.190 |
Why?
|
| Uterine Neoplasms | 1 | 2005 | 250 | 0.190 |
Why?
|
| Apolipoproteins E | 2 | 2013 | 130 | 0.190 |
Why?
|
| Risk Factors | 8 | 2020 | 5558 | 0.180 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 12 | 0.180 |
Why?
|
| Cohort Studies | 9 | 2020 | 2886 | 0.180 |
Why?
|
| Glomus Tumor | 1 | 2020 | 9 | 0.180 |
Why?
|
| Penicillin G Benzathine | 1 | 2020 | 5 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 20 | 0.180 |
Why?
|
| Sulfadiazine | 1 | 2020 | 24 | 0.180 |
Why?
|
| Treponema pallidum | 1 | 2020 | 8 | 0.180 |
Why?
|
| Trimethoprim | 1 | 2020 | 15 | 0.180 |
Why?
|
| Atherosclerosis | 2 | 2014 | 258 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2020 | 2327 | 0.180 |
Why?
|
| Epidermolysis Bullosa, Junctional | 1 | 2020 | 1 | 0.180 |
Why?
|
| Gentamicins | 1 | 2020 | 20 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 51 | 0.180 |
Why?
|
| Ambulatory Care | 2 | 2018 | 186 | 0.170 |
Why?
|
| Cause of Death | 2 | 2018 | 269 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 91 | 0.170 |
Why?
|
| Poroma | 1 | 2019 | 1 | 0.170 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 27 | 0.170 |
Why?
|
| Codon, Nonsense | 1 | 2020 | 43 | 0.170 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2019 | 7 | 0.170 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 19 | 0.170 |
Why?
|
| Syphilis | 1 | 2020 | 33 | 0.170 |
Why?
|
| Fontan Procedure | 1 | 2020 | 56 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 105 | 0.170 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.170 |
Why?
|
| Porokeratosis | 1 | 2019 | 3 | 0.170 |
Why?
|
| Primary Graft Dysfunction | 1 | 2020 | 41 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 83 | 0.170 |
Why?
|
| Intraoperative Care | 1 | 2020 | 85 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 124 | 0.170 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 1862 | 0.170 |
Why?
|
| Syndrome | 3 | 2005 | 450 | 0.170 |
Why?
|
| Cartilage | 2 | 2018 | 116 | 0.170 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 46 | 0.170 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 30 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2021 | 463 | 0.170 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 72 | 0.170 |
Why?
|
| Vasodilation | 1 | 2019 | 93 | 0.170 |
Why?
|
| Mice, Knockout | 8 | 2019 | 2016 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2020 | 111 | 0.160 |
Why?
|
| Hair Follicle | 1 | 2019 | 29 | 0.160 |
Why?
|
| Cheek | 2 | 2011 | 22 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 166 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2020 | 260 | 0.160 |
Why?
|
| Biphenyl Compounds | 2 | 2019 | 59 | 0.160 |
Why?
|
| Myocarditis | 1 | 2019 | 51 | 0.160 |
Why?
|
| Calcinosis | 2 | 2011 | 230 | 0.160 |
Why?
|
| Sternotomy | 1 | 2019 | 24 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 105 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 55 | 0.160 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 8 | 0.160 |
Why?
|
| Assisted Circulation | 1 | 2018 | 16 | 0.160 |
Why?
|
| Heart Function Tests | 1 | 2018 | 33 | 0.160 |
Why?
|
| Lunate Bone | 1 | 2018 | 2 | 0.160 |
Why?
|
| Guided Tissue Regeneration | 1 | 2018 | 7 | 0.160 |
Why?
|
| Acellular Dermis | 1 | 2018 | 5 | 0.160 |
Why?
|
| Donor Selection | 1 | 2019 | 77 | 0.160 |
Why?
|
| Trapezium Bone | 1 | 2018 | 7 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 511 | 0.160 |
Why?
|
| Reperfusion Injury | 1 | 2020 | 144 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 9 | 2019 | 3252 | 0.150 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1732 | 0.150 |
Why?
|
| Arthroplasty | 1 | 2018 | 28 | 0.150 |
Why?
|
| Atrial Appendage | 1 | 2018 | 33 | 0.150 |
Why?
|
| Pemphigoid, Bullous | 2 | 2021 | 12 | 0.150 |
Why?
|
| Subclavian Artery | 2 | 2015 | 43 | 0.150 |
Why?
|
| Alopecia | 2 | 2019 | 34 | 0.150 |
Why?
|
| Carpometacarpal Joints | 1 | 2018 | 14 | 0.150 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 53 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 119 | 0.150 |
Why?
|
| Rats | 8 | 2020 | 4048 | 0.150 |
Why?
|
| Enoxaparin | 1 | 2018 | 23 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 51 | 0.150 |
Why?
|
| Testosterone | 1 | 2019 | 272 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2020 | 254 | 0.150 |
Why?
|
| Equipment Failure | 4 | 2020 | 122 | 0.150 |
Why?
|
| Tattooing | 1 | 2017 | 5 | 0.150 |
Why?
|
| Erythema Nodosum | 1 | 2017 | 4 | 0.150 |
Why?
|
| Octreotide | 1 | 2018 | 28 | 0.150 |
Why?
|
| Graphite | 1 | 2017 | 12 | 0.150 |
Why?
|
| Mitral Valve | 1 | 2020 | 264 | 0.150 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 74 | 0.150 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2017 | 17 | 0.150 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 66 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 166 | 0.150 |
Why?
|
| Prostheses and Implants | 2 | 2018 | 125 | 0.150 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2017 | 5 | 0.150 |
Why?
|
| Nevus, Pigmented | 1 | 2018 | 52 | 0.150 |
Why?
|
| Skin Ulcer | 1 | 2017 | 25 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 103 | 0.150 |
Why?
|
| Thermodilution | 1 | 2017 | 19 | 0.140 |
Why?
|
| Illusions | 1 | 2017 | 12 | 0.140 |
Why?
|
| Rhinoplasty | 1 | 2018 | 35 | 0.140 |
Why?
|
| Surgical Flaps | 1 | 2020 | 250 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2019 | 353 | 0.140 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 116 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 159 | 0.140 |
Why?
|
| Desmocollins | 1 | 2017 | 3 | 0.140 |
Why?
|
| Prognosis | 6 | 2022 | 3798 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 281 | 0.140 |
Why?
|
| Atrial Flutter | 1 | 2017 | 36 | 0.140 |
Why?
|
| Gasotransmitters | 1 | 2017 | 14 | 0.140 |
Why?
|
| Myocardial Ischemia | 2 | 2017 | 162 | 0.140 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 23 | 0.140 |
Why?
|
| Drug Combinations | 3 | 2023 | 203 | 0.140 |
Why?
|
| Fibronectins | 1 | 2017 | 101 | 0.140 |
Why?
|
| Atrial Remodeling | 1 | 2017 | 24 | 0.140 |
Why?
|
| Cryptococcus neoformans | 1 | 2016 | 9 | 0.140 |
Why?
|
| Fluconazole | 1 | 2016 | 11 | 0.140 |
Why?
|
| Flucytosine | 1 | 2016 | 11 | 0.130 |
Why?
|
| Carbon Monoxide | 1 | 2017 | 93 | 0.130 |
Why?
|
| Amphotericin B | 1 | 2016 | 34 | 0.130 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 17 | 0.130 |
Why?
|
| Hydrogen Sulfide | 1 | 2017 | 52 | 0.130 |
Why?
|
| Visual Acuity | 2 | 2014 | 199 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 290 | 0.130 |
Why?
|
| Prosthesis Design | 4 | 2019 | 299 | 0.130 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 120 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 2767 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 146 | 0.130 |
Why?
|
| Coloring Agents | 2 | 2012 | 65 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2017 | 161 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 245 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2020 | 550 | 0.130 |
Why?
|
| Superoxide Dismutase | 3 | 2015 | 177 | 0.130 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 50 | 0.130 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2017 | 107 | 0.130 |
Why?
|
| Observer Variation | 2 | 2016 | 614 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2016 | 123 | 0.130 |
Why?
|
| Cyclosporine | 1 | 2016 | 238 | 0.130 |
Why?
|
| Rats, Inbred SHR | 2 | 2017 | 33 | 0.120 |
Why?
|
| Incidence | 5 | 2019 | 1603 | 0.120 |
Why?
|
| Lignans | 1 | 2015 | 6 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 189 | 0.120 |
Why?
|
| Phenotype | 3 | 2017 | 2456 | 0.120 |
Why?
|
| Lasers, Gas | 1 | 2014 | 4 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 2018 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1704 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2016 | 293 | 0.120 |
Why?
|
| Low-Level Light Therapy | 1 | 2014 | 15 | 0.120 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cephalosporins | 1 | 2014 | 24 | 0.120 |
Why?
|
| LIM Domain Proteins | 1 | 2014 | 25 | 0.120 |
Why?
|
| Conjunctiva | 1 | 2014 | 19 | 0.120 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2014 | 22 | 0.120 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2014 | 14 | 0.120 |
Why?
|
| Amnion | 1 | 2014 | 16 | 0.120 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2014 | 19 | 0.120 |
Why?
|
| Toxoplasmosis | 1 | 2015 | 66 | 0.120 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 360 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 1801 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2016 | 196 | 0.120 |
Why?
|
| Refraction, Ocular | 1 | 2014 | 9 | 0.120 |
Why?
|
| Melkersson-Rosenthal Syndrome | 1 | 2014 | 1 | 0.120 |
Why?
|
| Posture | 1 | 2014 | 125 | 0.120 |
Why?
|
| Sulfonylurea Receptors | 1 | 2014 | 50 | 0.110 |
Why?
|
| Eyelid Diseases | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cells, Cultured | 6 | 2020 | 2887 | 0.110 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2014 | 10 | 0.110 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 160 | 0.110 |
Why?
|
| Gastrointestinal Agents | 2 | 2018 | 174 | 0.110 |
Why?
|
| Nails | 1 | 2014 | 11 | 0.110 |
Why?
|
| Infant | 3 | 2021 | 3188 | 0.110 |
Why?
|
| Mutation, Missense | 2 | 2013 | 281 | 0.110 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 60 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2018 | 543 | 0.110 |
Why?
|
| Luciferases | 1 | 2014 | 128 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 354 | 0.110 |
Why?
|
| Connective Tissue Diseases | 1 | 2014 | 70 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 528 | 0.110 |
Why?
|
| Myosin Heavy Chains | 1 | 2014 | 92 | 0.110 |
Why?
|
| DNA Damage | 1 | 2016 | 373 | 0.110 |
Why?
|
| Electrocardiography | 4 | 2019 | 497 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.110 |
Why?
|
| Exosomes | 1 | 2014 | 53 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 888 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1066 | 0.110 |
Why?
|
| Edema | 1 | 2014 | 70 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 326 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2014 | 50 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 110 | 0.110 |
Why?
|
| Suture Techniques | 1 | 2014 | 144 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 1098 | 0.110 |
Why?
|
| Vasculitis | 2 | 2013 | 40 | 0.110 |
Why?
|
| Genes, Reporter | 1 | 2014 | 274 | 0.110 |
Why?
|
| Carmine | 1 | 2012 | 1 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 245 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2677 | 0.110 |
Why?
|
| Foam Cells | 1 | 2012 | 17 | 0.110 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 9 | 0.110 |
Why?
|
| Illinois | 3 | 2019 | 485 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2014 | 446 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 146 | 0.110 |
Why?
|
| Reoperation | 3 | 2020 | 604 | 0.100 |
Why?
|
| Mucins | 1 | 2012 | 39 | 0.100 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2012 | 44 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 280 | 0.100 |
Why?
|
| Electrophysiological Phenomena | 1 | 2012 | 51 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 744 | 0.100 |
Why?
|
| Quinolines | 1 | 2013 | 86 | 0.100 |
Why?
|
| Weight Gain | 1 | 2013 | 119 | 0.100 |
Why?
|
| Axilla | 1 | 2012 | 103 | 0.100 |
Why?
|
| Breath Tests | 1 | 2012 | 57 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2012 | 169 | 0.100 |
Why?
|
| Models, Cardiovascular | 1 | 2012 | 107 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2020 | 1237 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 563 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 112 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 60 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 557 | 0.100 |
Why?
|
| Hydrogen | 1 | 2012 | 48 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2012 | 138 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 338 | 0.100 |
Why?
|
| Valsartan | 2 | 2023 | 11 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 147 | 0.100 |
Why?
|
| Collagen Type VII | 1 | 2011 | 3 | 0.100 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2011 | 2 | 0.100 |
Why?
|
| Cell Communication | 1 | 2012 | 200 | 0.100 |
Why?
|
| Lung | 1 | 2018 | 1292 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 692 | 0.100 |
Why?
|
| Dermatologic Agents | 1 | 2012 | 73 | 0.100 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 111 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2018 | 785 | 0.100 |
Why?
|
| Biomarkers | 3 | 2018 | 1778 | 0.100 |
Why?
|
| Sodium Channels | 1 | 2012 | 130 | 0.100 |
Why?
|
| Rifamycins | 1 | 2011 | 6 | 0.090 |
Why?
|
| S100A12 Protein | 4 | 2013 | 10 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 365 | 0.090 |
Why?
|
| Disease Progression | 3 | 2020 | 1469 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 471 | 0.090 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 244 | 0.090 |
Why?
|
| Homeostasis | 1 | 2013 | 418 | 0.090 |
Why?
|
| Environment | 1 | 2013 | 225 | 0.090 |
Why?
|
| Ion Channels | 1 | 2012 | 246 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 251 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 855 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2013 | 299 | 0.090 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 126 | 0.090 |
Why?
|
| Muscle Contraction | 3 | 2019 | 286 | 0.090 |
Why?
|
| Histones | 1 | 2013 | 333 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2020 | 3771 | 0.090 |
Why?
|
| Fibroblasts | 4 | 2016 | 759 | 0.090 |
Why?
|
| Mitochondria, Muscle | 1 | 2010 | 27 | 0.090 |
Why?
|
| Recurrence | 3 | 2018 | 1145 | 0.090 |
Why?
|
| Feces | 1 | 2012 | 333 | 0.090 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Ergocalciferols | 1 | 2010 | 38 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2011 | 169 | 0.090 |
Why?
|
| Child | 3 | 2021 | 7240 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2010 | 72 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 118 | 0.090 |
Why?
|
| Neural Crest | 1 | 2010 | 33 | 0.080 |
Why?
|
| NAD | 1 | 2009 | 72 | 0.080 |
Why?
|
| Allografts | 2 | 2021 | 184 | 0.080 |
Why?
|
| Rare Diseases | 2 | 2020 | 69 | 0.080 |
Why?
|
| Lymphatic System | 2 | 2019 | 55 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 64 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2013 | 906 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 231 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 6783 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2009 | 308 | 0.080 |
Why?
|
| Osteogenesis | 1 | 2010 | 258 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1082 | 0.080 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 110 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2331 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2009 | 127 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 171 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1670 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2013 | 666 | 0.080 |
Why?
|
| Vitamin D | 1 | 2010 | 269 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1533 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 6409 | 0.070 |
Why?
|
| Tissue Donors | 2 | 2021 | 505 | 0.070 |
Why?
|
| Hydroquinones | 1 | 2007 | 8 | 0.070 |
Why?
|
| Forehead | 1 | 2007 | 15 | 0.070 |
Why?
|
| Hair Removal | 1 | 2007 | 14 | 0.070 |
Why?
|
| Exercise Test | 2 | 2019 | 166 | 0.070 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 490 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 952 | 0.070 |
Why?
|
| Radiation-Protective Agents | 1 | 2007 | 98 | 0.070 |
Why?
|
| Cell Movement | 1 | 2010 | 787 | 0.070 |
Why?
|
| Reference Values | 2 | 2018 | 662 | 0.070 |
Why?
|
| Fumarate Hydratase | 1 | 2005 | 6 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 953 | 0.070 |
Why?
|
| United States | 4 | 2021 | 7108 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 384 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 195 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 1497 | 0.060 |
Why?
|
| Alopecia Areata | 1 | 2005 | 4 | 0.060 |
Why?
|
| Pregnancy | 1 | 2013 | 3046 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 682 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 90 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2007 | 301 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 727 | 0.060 |
Why?
|
| Point Mutation | 1 | 2005 | 246 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2004 | 177 | 0.060 |
Why?
|
| Random Allocation | 2 | 2018 | 327 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2020 | 720 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 346 | 0.060 |
Why?
|
| Dacryocystorhinostomy | 1 | 2004 | 4 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 278 | 0.060 |
Why?
|
| Acetylation | 2 | 2015 | 132 | 0.060 |
Why?
|
| Collagen | 2 | 2019 | 294 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 1880 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 226 | 0.050 |
Why?
|
| Elastic Tissue | 2 | 2014 | 18 | 0.050 |
Why?
|
| Animals, Newborn | 2 | 2014 | 524 | 0.050 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2021 | 9 | 0.050 |
Why?
|
| Pemphigus | 1 | 2021 | 14 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2013 | 2026 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2021 | 78 | 0.050 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2013 | 19 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 700 | 0.050 |
Why?
|
| ABO Blood-Group System | 1 | 2021 | 58 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 83 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 164 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2013 | 140 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.050 |
Why?
|
| Radiography | 1 | 2003 | 808 | 0.050 |
Why?
|
| Bilirubin | 1 | 2021 | 131 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2019 | 872 | 0.050 |
Why?
|
| Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 2013 | 136 | 0.050 |
Why?
|
| Aorta | 2 | 2013 | 289 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 44 | 0.050 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2020 | 9 | 0.040 |
Why?
|
| Syphilis, Cutaneous | 1 | 2020 | 3 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2020 | 26 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2020 | 73 | 0.040 |
Why?
|
| California | 1 | 2020 | 146 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2020 | 59 | 0.040 |
Why?
|
| Epigastric Arteries | 1 | 2020 | 9 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2019 | 6 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 28 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 56 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Exanthema | 1 | 2020 | 40 | 0.040 |
Why?
|
| Dissection | 1 | 2020 | 44 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 2020 | 108 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2021 | 171 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
| Reperfusion | 1 | 2020 | 32 | 0.040 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 9 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2019 | 17 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 84 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 41 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2020 | 84 | 0.040 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2019 | 8 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 49 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 296 | 0.040 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2019 | 37 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 75 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 93 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 131 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 50 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2020 | 146 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 152 | 0.040 |
Why?
|
| Neck | 1 | 2019 | 104 | 0.040 |
Why?
|
| Epidermis | 1 | 2019 | 102 | 0.040 |
Why?
|
| Head | 1 | 2019 | 136 | 0.040 |
Why?
|
| Hindlimb | 1 | 2019 | 96 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 185 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 115 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 667 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2020 | 230 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 372 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 995 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 289 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 147 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2019 | 309 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2018 | 131 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 64 | 0.040 |
Why?
|
| Rats, Nude | 1 | 2018 | 25 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 153 | 0.040 |
Why?
|
| Ink | 1 | 2017 | 4 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 39 | 0.040 |
Why?
|
| Mutation | 1 | 2009 | 4168 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 83 | 0.040 |
Why?
|
| Fascia | 1 | 2018 | 31 | 0.040 |
Why?
|
| Ischemia | 1 | 2020 | 253 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2018 | 196 | 0.040 |
Why?
|
| Thyroxine | 1 | 2019 | 355 | 0.040 |
Why?
|
| Ophthalmologists | 1 | 2017 | 5 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 785 | 0.040 |
Why?
|
| Neutropenia | 1 | 2018 | 214 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 866 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2019 | 243 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 983 | 0.040 |
Why?
|
| Graft Survival | 1 | 2021 | 908 | 0.040 |
Why?
|
| Protein Binding | 2 | 2013 | 1491 | 0.040 |
Why?
|
| Rabbits | 1 | 2018 | 640 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2017 | 96 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 201 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2017 | 52 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Rats, Inbred WKY | 1 | 2017 | 32 | 0.040 |
Why?
|
| Radiologists | 1 | 2017 | 50 | 0.040 |
Why?
|
| Tachycardia | 1 | 2017 | 37 | 0.030 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2017 | 44 | 0.030 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2017 | 35 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 323 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 808 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 358 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 147 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 399 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 164 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 347 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1250 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 33 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 97 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 408 | 0.030 |
Why?
|
| Thrombin | 1 | 2016 | 61 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 69 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 590 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2016 | 21 | 0.030 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 28 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2016 | 25 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 9340 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 45 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2016 | 141 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 749 | 0.030 |
Why?
|
| Atovaquone | 1 | 2015 | 3 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 117 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 1084 | 0.030 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2015 | 5 | 0.030 |
Why?
|
| Phenylephrine | 1 | 2015 | 36 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 55 | 0.030 |
Why?
|
| Isoproterenol | 1 | 2015 | 62 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 347 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1075 | 0.030 |
Why?
|
| Respiration | 1 | 2017 | 267 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 77 | 0.030 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1434 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 422 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 261 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1866 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 983 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1169 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 275 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 91 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2015 | 48 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 755 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 155 | 0.030 |
Why?
|
| KATP Channels | 1 | 2014 | 19 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 70 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 29 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 85 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.030 |
Why?
|
| Carotid Body | 1 | 2017 | 236 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1929 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 696 | 0.030 |
Why?
|
| Aortography | 1 | 2013 | 65 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 55 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2014 | 134 | 0.030 |
Why?
|
| Body Weight | 1 | 2014 | 453 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2013 | 15 | 0.030 |
Why?
|
| Hypotension | 1 | 2013 | 71 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2012 | 12 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 85 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 464 | 0.030 |
Why?
|
| Omalizumab | 1 | 2012 | 8 | 0.030 |
Why?
|
| Leucine | 1 | 2012 | 60 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2012 | 49 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2012 | 32 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 846 | 0.030 |
Why?
|
| Zinc | 1 | 2013 | 95 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 1061 | 0.030 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2012 | 32 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 145 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 696 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 82 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 119 | 0.020 |
Why?
|
| Thiazoles | 1 | 2012 | 127 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 114 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 302 | 0.020 |
Why?
|
| Eosinophils | 1 | 2012 | 194 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 374 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 168 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 283 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 678 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1682 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 994 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 236 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2655 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 107 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 776 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 252 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2014 | 677 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 726 | 0.020 |
Why?
|
| Connexins | 1 | 2012 | 202 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1730 | 0.020 |
Why?
|
| Rats, Mutant Strains | 1 | 2010 | 23 | 0.020 |
Why?
|
| Losartan | 1 | 2010 | 30 | 0.020 |
Why?
|
| SOXD Transcription Factors | 1 | 2010 | 1 | 0.020 |
Why?
|
| Butadienes | 1 | 2010 | 34 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 95 | 0.020 |
Why?
|
| Renin | 1 | 2010 | 67 | 0.020 |
Why?
|
| Biomimetics | 1 | 2010 | 31 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2010 | 27 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 82 | 0.020 |
Why?
|
| Aggrecans | 1 | 2010 | 43 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2012 | 284 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2010 | 65 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2009 | 24 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2009 | 67 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 444 | 0.020 |
Why?
|
| Vitamins | 1 | 2010 | 83 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 231 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 2009 | 38 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 158 | 0.020 |
Why?
|
| Stress Fibers | 1 | 2009 | 24 | 0.020 |
Why?
|
| Chromatin | 1 | 2012 | 403 | 0.020 |
Why?
|
| Catalase | 1 | 2009 | 49 | 0.020 |
Why?
|
| Nitriles | 1 | 2010 | 156 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 313 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 1121 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 323 | 0.020 |
Why?
|
| Laminin | 1 | 2009 | 89 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 961 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1309 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 349 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2009 | 228 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 543 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1227 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 793 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 262 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1744 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 257 | 0.020 |
Why?
|
| Antioxidants | 1 | 2009 | 226 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 885 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 644 | 0.020 |
Why?
|
| Indiana | 1 | 2006 | 14 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 2329 | 0.020 |
Why?
|
| Etanercept | 1 | 2005 | 33 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2006 | 174 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 261 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2004 | 57 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1718 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2006 | 333 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 523 | 0.010 |
Why?
|